Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Men’s Heart Disease Partly Due to Low Estrogen

March 26, 2015 8:52 am | by Cynthia Fox, Science Writer | Articles | Comments

One reason men have more heart disease than women is the very fact that they are men, reports Harvard University endocrinologist Evelyn Yu, M.D., MS.c. Both men’s higher testosterone levels and their lower estrogen levels, play a role. Read more...

TOPICS:

Ebola More Deadly for Young Children

March 26, 2015 8:37 am | by Sam Wong, Imperial College London | News | Comments

An international group of scientists analyzed data on Ebola cases in children under 16 during the current outbreak in Guinea, Liberia and Sierra Leone, comparing them to cases in adults. Read more...

TOPICS:

GSK Gains Japanese Approval for COPD Therapy

March 26, 2015 8:25 am | News | Comments

Following this approval, it is expected that launch will take place in Japan in 2015. Read more...

TOPICS:
Advertisement

Ugandan Official: Typhoid Sickens Hundreds in Capital

March 25, 2015 2:15 pm | by Rooney Muhumuza, Associated Press | News | Comments

An outbreak of typhoid fever has infected hundreds of people in the Ugandan capital, Kampala, and looks likely to spread as the rainy season gets under way. Read more...

TOPICS:

Study Announces Durable Ebola Vaccine

March 25, 2015 2:10 pm | by Andrew Gould, University of Plymouth | News | Comments

A new study shows the durability of a novel CMV-based Ebola virus vaccine strategy that may eventually have the potential to reduce ebola virus infection in wild African ape species. Read more...

TOPICS:

A Look at Some Key Statistics on Rare Diseases in the U.S.

March 25, 2015 1:45 pm | by The Associated Press | News | Comments

The global pharmaceutical industry is make huge investments in treatments for rare diseases, which once drew little interest from major drugmakers. Read more...

TOPICS:

FDA Approves Anthrax Treatment

March 25, 2015 1:10 pm | by Stephanie Guzowski, Editor | News | Comments

The Food and Drug Administration (FDA) yesterday approved Emergent BioSolutions’ infusible drug Anthrasil for use in combination with antibiotics to treat inhalational anthrax, which happens when bacterial spores that carry anthrax are breathed in. Read more...

TOPICS:

Sepsis-Specific Treatment Market Will Expand from 2016, Reach $354M by 2021

March 25, 2015 12:28 pm | by Marc C. Hansel, Ph.D., GlobalData Infectious Diseases Analyst | Articles | Comments

GlobalData's latest report states that this growth will be driven by the increased uptake of novel therapies. Read more...

TOPICS:
Advertisement

Science, Patients Driving Rare Disease Drug Research Surge

March 25, 2015 11:34 am | by Linda A. Johnson, AP Business Writer | News | Comments

The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers but now point the way toward a new era of innovative therapies and big profits. Read more...

TOPICS:

Antibiotics Pipeline Boasts 741 Products, but First-in-class Development Remains Low: GBI Research

March 25, 2015 9:48 am | News | Comments

While antibiotics boast a vast pipeline, with 741 products currently in development, the majority is dominated by generics, as weak financial incentives and high failure rates have discouraged innovation, says business intelligence provider GBI Research. Read more..

TOPICS:

Biocept Enters Clinical Collaboration With UC, San Diego Moores Cancer Center

March 25, 2015 9:42 am | News | Comments

Biocept, Inc., a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center.

TOPICS:

Non-FDA Approved Hormone Therapies on the Rise

March 25, 2015 9:36 am | by Cynthia Fox, Science Writer | Articles | Comments

Use of potentially risky, non-FDA approved hormone therapies may soon be as common as use of FDA-approved hormone therapies, according to a study by University of Virginia gynecology researcher JoAnn Pinkerton. Read more..

TOPICS:

Blueprint Medicine Files for IPO

March 25, 2015 9:30 am | by Ryan Bushey, Associate Editor | Articles | Comments

The biotech firm is making a big bet on the success of its precision therapies. Read more...

TOPICS:

Takeda Licenses Rights to Use Immunogen's Technology to Develop Anticancer Therapies

March 25, 2015 8:44 am | News | Comments

Takeda will use the technology to develop and commercialize targeted anticancer therapeutics to up to two undisclosed  targets. Read more...

TOPICS:

GSK Seeks Early Drug Discovery Partnerships with Academics in Europe, Canada, and U.S.

March 25, 2015 8:37 am | News | Comments

This program designed to accelerate the translation of early-stage research into game-changing new medicines. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading